Welcome. I was wondering if the HIV comments during the State of the Union would bring in some interested parties. Unfortunately, being on the OTC and trading at $0.50/share will keep many people from ever giving it a second thought, which is why, as you say, more people haven't found this incredibly exciting. That will turn out to be a costly mistake for them, because BP will not have that luxury when cancer data starts coming out.
Really, Gilead doesn't have that luxury now, what with the CAR-T write offs and the latest failures in late-stage NASH treatments. If somebody moves on this for the cancer indication, you better believe they'll be happy to steal GILD's HIV revenue stream as well. They should just pull the trigger before cancer data, if they even have the opportunity to do that at this point.